Daily News Podcast

Finally, new migraine drugs

Publish date: August 1, 2018

 

Successful phase 3 data for new headache medications (rimegepant, ubrogepant, lasmiditan) are finally raining in after a lengthy drought. Also today, interferon status and family history predict autoimmune connective tissue disease, steroid injection before rotator cuff repair predicts revision, and the CMS resumes risk adjustment payments for 2017. Listen to the MDedge Daily News for today’s top news.

Recommended Reading

Brain damage, slight benefit seen in epinephrine cardiac arrest
MDedge Internal Medicine
Is fibromyalgia one disorder – or two?
MDedge Internal Medicine
Is fish oil’s heart benefit a fish tale?
MDedge Internal Medicine
Mild cognitive impairment risk slashed by 19% in SPRINT MIND
MDedge Internal Medicine
Blood pressure meds cut cognitive impairment risk
MDedge Internal Medicine
Antibody cleared amyloid plaques, slowed cognitive decline
MDedge Internal Medicine
Oral drug seen preventing angioedema attacks
MDedge Internal Medicine
Various soft tissue recovery methods get different results
MDedge Internal Medicine
Free skin cancer screening highlights need
MDedge Internal Medicine
Valsartan cancer risk is low
MDedge Internal Medicine